Kristin Yarema describes how she believes that honing in on the right preconditioning regimen might be a success factor.

Stuart Arbuckle describes the approval and launch dynamics of this gene-edited cell therapy.

Hervé Hoppenot discusses Incyte's #ASH23 presentations, the company's pipeline, success in dermatology, and how he thinks about Jakafi.

Dinesh Patel describes the science behind Protagonist's polycythemia vera program and oral IL23.

Madeleine Armstrong shares her thoughts on CAR-T data in lupus, the menin inhibitor class, BCMA CAR-T, and Regeneron's bi-specifics.

Rami Elghandour compares Arcellx's estimated 28 month PFS to Carvykti and gives his take on the recent FDA notice about CAR-T.

Mara Goldstein previews key #ASH23 data from Incyte, Syndax, Autolus, Corvus, IN8bio, and more.

Michael Henderson describes the rationale behind Apogee's IL13 program and how it has been designed to have a longer half-life.

Greg Yap describes how his firm evaluates AI companies and lists other technology transformations to watch in the sector.

Surbhi Sarna explains how Y Combinator invests in healthcare and biotech entrepreneurs and how the application process works.

Vir's new CEO gives an overview of the company's programs and discusses future plans to expand into autoimmune disease and oncology.

Amit Etkin says that psychiatric conditions have been treated too broadly in the past.

Nevan Krogan, Director of the Quantitative Biosciences Institute at UCSF, expands on work posted to bioRxiv today.

Andy Hsieh comments on AbbVie's buyout of ImmunoGen, gives a deep dive into radiopharmaceutical, and discusses AASLD, Seagen, and Icosavax.

Simeon George talks about his firm's philosophy, advice for biotech entrepreneurs, and discusses a busy few weeks of news.

Neil Kumar discusses the competitive profile he sees emerging for acoramidis, a big phase 3 in ADH1 and investing in early science.

Jakob Dupont says he is focused on clinical stage companies or ones that are months within IND.

President and CEO Robert Blum describes aficamten's mechanism, the trial's study design, and reflects on Cytokinetics' 25 years.

Co-founder, Chairman & CEO Ken Drazan explains the array of applications that Arsenal engineers into its CAR-T cells.

Evan Seigerman discusses news from #AHA23, what's going on with Structure, Verve's polarizing result, Neurocrine, Vertex, Pfizer and more.